Media

Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting

Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion

Nordic Nanovector provides update on the PARADIGME clinical trial

Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome

Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting

Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection

Strongbridge Biopharma plc to Host Investor and Analyst Day on April 5, 2018